The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

The key benefit of zerlasiran’s approach is its ability to directly target and silence the gene responsible for Lp(a) ...

Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...

Participants who were given 150,000 endothelial cells experienced an average gain of 11 letters in Best Corrected Visual ...

According to the company the compound could potentially be the world’s first US Food and Drug Administration (FDA) approved ...

The trial is structured as a non-randomised, open-label study in patients with relapsed, resistant or metastatic HPV-related ...

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...